Changes in Hong Kong stocks | Yingen Biotech (09606) rose more than 6% in the afternoon, and the total volume of BD cooperative transactions exceeded 7 billion US dollars. The company explored and switched to a joint developer in the US

The Zhitong Finance App learned that Yingen Bio-B (09606) rose more than 6% in the afternoon. As of press release, it rose 5.74% to HK$186.1, with a turnover of HK$143 million.

Huachuang Securities released a research report saying that Yingen has reached cooperation/cooperation with 7 domestic and foreign pharmaceutical companies on 6 molecular and innovative pharmaceutical companies on 6 molecular and DUPAC™ innovation payload platforms. Currently, it has only received about 550 million US dollars in down payments and milestone payments. Unconfirmed milestone revenue of over 6.5 billion US dollars and high single-digit to low double-digit sales shares after drug marketing have provided a solid foundation for subsequent continuous cash flow inflows.

In addition, Yingen chose to act on the most definitive B7-H3ADC, and will fully share DB-1311/BNT324's development costs in the US market with BioNTech and share its profits and losses after commercialization. Compared with the single-digit to low-double-digit sales share in ordinary BD transactions, it is expected to further fulfill the commercial value in the US market. The bank pointed out that the company's product pipeline is gradually entering an advanced stage, and 2027 will be the first year of commercialization.